HomeAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
Previous close
$18.09
Day range
$17.52 - $18.45
Year range
$9.50 - $18.85
Market cap
1.60B USD
Avg Volume
901.72K
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 19.45M | — |
Operating expense | 43.66M | 88.06% |
Net income | -28.79M | -4.87% |
Net profit margin | -147.98 | — |
Earnings per share | -0.29 | 34.34% |
EBITDA | -24.46M | -8.08% |
Effective tax rate | 0.35% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 105.11M | 8.92% |
Total assets | 164.70M | 24.03% |
Total liabilities | 76.96M | -50.00% |
Total equity | 87.74M | — |
Shares outstanding | 90.58M | — |
Price to book | 18.46 | — |
Return on assets | -33.85% | — |
Return on capital | -43.16% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -28.79M | -4.87% |
Cash from operations | -28.03M | -82.41% |
Cash from investing | 27.93M | 22.09% |
Cash from financing | -21.11M | -418.80% |
Net change in cash | -20.64M | -255.62% |
Free cash flow | -19.58M | -188.64% |
About
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Founded
1990
Website
Employees
154
